Annexon (NASDAQ:ANNX – Get Free Report) and Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.
Profitability
This table compares Annexon and Day One Biopharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Annexon | N/A | -38.99% | -33.90% |
| Day One Biopharmaceuticals | N/A | -22.40% | -19.79% |
Earnings and Valuation
This table compares Annexon and Day One Biopharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Annexon | N/A | N/A | -$134.24 million | ($1.05) | -3.86 |
| Day One Biopharmaceuticals | N/A | N/A | -$188.92 million | ($1.03) | -11.95 |
Analyst Recommendations
This is a summary of current recommendations and price targets for Annexon and Day One Biopharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Annexon | 0 | 0 | 6 | 0 | 3.00 |
| Day One Biopharmaceuticals | 0 | 1 | 7 | 1 | 3.00 |
Annexon currently has a consensus price target of $15.80, indicating a potential upside of 289.64%. Day One Biopharmaceuticals has a consensus price target of $35.86, indicating a potential upside of 191.40%. Given Annexon’s higher probable upside, equities analysts plainly believe Annexon is more favorable than Day One Biopharmaceuticals.
Volatility & Risk
Annexon has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.46, suggesting that its share price is 246% less volatile than the S&P 500.
Insider & Institutional Ownership
88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. 12.7% of Annexon shares are owned by insiders. Comparatively, 8.4% of Day One Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Day One Biopharmaceuticals beats Annexon on 6 of the 11 factors compared between the two stocks.
About Annexon
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.
